Capital & FinanceEvent: August 31, 2026
Hemaptics notes that Meteora3D has been awarded a $1.25M SBIR Phase II grant from the NSF to continue enhancing its patent pending technology.
Published
Signal category
Capital & Finance
Quote
“Meteora3D has been awarded a $1.25M SBIR Phase II grant from the NSF”
— Ethan Cohen|Hemaptics team
Company
Hemaptics
HemaLogiX optimizes the use of blood products, resulting in improved patient outcomes and lower costs.
- Industry
- Hospitals and Health Care
- Location
- Cleveland, US
- Company size
- 4 employees
HemaLogiX® is an EMR integrated software system that improves transfusion utilization, resulting in lower costs and improved patient outcomes. HemaLogiX increases awareness of evidence-based practice.
Founded 2019